$ENDV SofPulse, a FDA Cleared medical device company specializing in non-invasive microcurrent therapy, has undergone several valuations in recent years:
2018 Valuation: A third-party assessment valued SofPulse's intellectual property and assets at $75 million.
2023 Agreement: Endonovo Therapeutics, the parent company, entered into a definitive agreement to sell SofPulse's business and medical intellectual property to SofPulse, Inc. for a minimum of $50 million. The final purchase price is subject to an updated valuation by a qualified third party, with estimates ranging between $50 million to $100 million.
Market Data 
Markets 
AI
